Brief: Allarity Therapeutics Doses First Patient In Phase 1B Clinical Trial Evaluating Dovitinib, Stenoparib Combination In Advanced Solid Tumors
20/03/2023 11:09
March 20 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B
CLINICAL
TRIAL EVALUATING DOVITINIB AND STENOPARIB COMBINATION IN
ADVANCED SOLID TUMORS
* ALLARITY THERAPEUTICS : ANTICIPATES THAT COMBINATION OF
PAN-TKI
DOVITINIB AND PARP INHIBITOR STENOPARIB MAY GENERATE SYNERGISTIC
ANTI-CANCER ACTIVITY
Source text for Eikon: ID:nGNX2TlZPy
Further company coverage: ALLR.O
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic